Simplify Logo
Intuitive Surgical

Intuitive Surgical

Manufactures robotic surgical systems and services

Clinical Research Engineer - Future Forward

Full-Time
$132k - $223.5k/yr

+ Incentives + Equity

Senior
Bachelor's
Sunnyvale, CA, USA
Remote

Must commute or relocate to Sunnyvale, California.

About the job

Requirements
  • A minimum of a B.S. in Biomedical Engineering, Mechanical Engineering, or a similar field.
  • At least 5 years of related experience in clinical engineering and/or product development within the medical device industry.
  • Fluency in medical procedure terminology and sound knowledge of anatomy.
  • Ability to understand complex robotic systems and software algorithms.
  • Experience working in an operating room or interventional suite environment.
  • Experience collaborating with physicians and collecting feedback on clinical use of the product.
  • Excellent mechanical and technical aptitude and intuition for spatial relations, including the ability to understand complex mechanical products.
  • Excellent analytical capability and practical skills to develop and test a clinical hypothesis and draw succinct conclusions.
  • Excellent teamwork skills with a proven ability to cultivate collaboration across multiple disciplines to ensure timely project success.
  • Proven success recognizing critical issues and driving them to closure by taking coordinated action.
  • Product development and Design Controls experience.
  • Familiarity with intellectual property development and patent assessment.
  • Effective verbal, written, and presentation communication skills.
  • Ability to work independently with minimal supervision.
  • Ability to react quickly under pressure.
  • Availability to work full-time and commute or relocate to Sunnyvale, California.
Responsibilities
  • Research disease states and medical technologies associated with new business opportunities and apply in-depth knowledge to become an expert within the company on new products and their clinical application.
  • Collaborate with engineers and physicians to define clinical performance goals and potential risks for new products in early-phase development.
  • Work with key opinion leaders, subject matter experts, physicians, and other stakeholders to identify clinical goals and translate those needs into user-centric design and development of new platforms, procedures, instruments, and accessories.
  • Collaborate with design engineering, regulatory, human factors, industrial design, training, marketing, and other organizations while leading the clinical aspects of new programs and platform development.
  • Develop and execute clinical derisking pathways, including preclinical and clinical feasibility studies.
  • Contribute to market development and segmentation for new clinical applications.
  • Develop novel clinical models and metrics for technology evaluation and prototype performance assessment.
  • Develop novel procedures and workflows for new technologies.
  • Design, develop, and execute clinical evaluations of prototypes and translate feedback to the engineering team for technology acceleration.
  • Conduct design iteration assessments of products internally and with external key opinion leaders.
  • Identify and drive product enhancements and new product ideas by applying an analytical approach to understanding the clinical needs of physicians and users.
  • Develop and execute a preclinical evaluation strategy in advance of human trials and regulatory submissions.
  • Lead and execute early-stage feasibility, pilot, and pivotal studies to support technology development for regulatory and reimbursement strategies.
  • Develop intellectual property for novel clinical applications and technologies.
  • Perform other duties as required to support the company's overall strategy and goals.
Desired Qualifications
  • Experience with on-site clinical trial support.

About the company

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, with 468 da Vinci placements.
  • Intuitive opened a 316,000-square-foot Penang plant, creating 1,200 jobs by 2032.
  • Direct Italy-Spain-Portugal distribution expanded March 2, 2026, strengthening European control.

What critics are saying

  • FDA logged a February 18, 2026 class-2 recall for da Vinci 5 software crashes.
  • Johnson & Johnson's Ottava won FDA approval in summer 2026, attacking Intuitive's core.
  • Medtronic Hugo and J&J Ottava commoditize robotics, breaking da Vinci's moat by 2028.

What makes Intuitive Surgical unique

  • da Vinci 5 won FDA cardiac clearance on January 26, 2026.
  • Ion and da Vinci generate recurring instruments, accessories, and service revenue.
  • da Vinci SP earned CE mark expansion on September 15, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.